New Technology Could Help Diagnose Sepsis in Hours
|
By LabMedica International staff writers Posted on 08 Nov 2016 |

Image: A new microfluidics chip being developed for a blood test to rapidly diagnose sepsis would enable doctors to intervene sooner and as necessary, as well as to monitor treatment progress (Photo courtesy of Pappas Lab / Texas Tech University).
Researchers have developed a microfluidics chip that detected mock-sepsis conditions within a few hours, instead of at least two days by currently used methods. As sepsis left untreated can be fatal in as little as two days, a rapid blood test would provide medical professionals with a critical window of time in which to begin early antibiotics treatment of diagnosed patients.
“Normally when you detect sepsis, you do it through bacterial culture; that takes two days on the short end to 15 days on the long end. Most people die of sepsis at two days. The detection currently is on the exact same time scale as mortality, so we’re trying to speed that up,” said Dimitri Pappas, associate professor of chemistry at Texas Tech University (Lubbock, TX, USA), “Instead of the bacteria, we’re looking at the body’s immune response to those bacteria, because that’s what you really care about: the bacteria cause the infection, but it’s the body’s response that causes sepsis.” It begins with a systemic inflammatory response then progresses into sepsis and eventually septic shock, in which blood pressure plummets and organs fail.
“In the elderly, in people who are immune-compromised – people who have had surgeries, for example, or burns or they’re already fighting off infection – and in children as well, you see a runaway immune response where the body’s act of saving itself can actually be lethal,” said Prof. Pappas. When not fatal, sepsis can result in amputation of a limb or prolonged hospitalization.
Sepsis is suspected by a patient’s abnormal body temperature and rapid heart and breathing rates. “Those are all incredibly crude measurements,” said Prof. Pappas, “It leads to a lot of false positives.” Because doctors know the bacterial culture likely will take longer than a septic patient’s life span, they often order treatment immediately. “The way they treat sepsis right now is through a massive antibiotic administration,” said Prof. Pappas “That’s good, actually, but if you do it prophylactically and when it’s not needed, you’re basically helping create drug-resistant bacteria. So there’s a need to detect sepsis and to treat it but not to over treat it.”
To successfully treat septic patients, doctors need two critical pieces of information: the microorganism causing the infection and whether it can be eradicated by antibiotics. “Waiting for that information over several days is one of the main problems and reasons for the devastating outcomes,” said Dr. John Griswold, professor and chair emeritus, Department of Surgery, TTU’s Health Sciences Center, “Dr. Pappas has developed a test that should give us at least the indication of bacterial invasion within a matter of hours as opposed to days. The sooner we have an indication of microorganism invasion, the sooner we are on the path to successful treatment of these very sick patients.” Prof. Griswold added that sepsis is considered one of the most costly diseases in healthcare.
Prof. Pappas and graduate student Ye Zhang recently filed a provisional patent for a microfluidics chip that can speed up detection. “We can take a blood sample, introduce it into this chip and capture one cell type or move fluids around and add chemicals to dye the cells certain colors and do diagnostic measurements,” said Prof. Pappas.
Using their chip, a sepsis diagnosis can be confirmed in just four hours. “That rapid detection will let doctors intervene sooner and intervene when necessary, but it also allows them not just to detect it but to follow up treatment,” said Prof. Pappas, “you can follow and retest them over time to make sure the body’s response is returning to normal.”
Another advantage is that the chip requires less than a drop of blood per test. “It’s so minimal we could do this multiple times throughout the course of the treatment of the patient. If they’re not septic at hour zero, but they still look septic by other methods, we could test them in six hours and see if they’ve progressed or not,” said Prof. Pappas.
The chips are designed to detect certain white blood cells activated by the immune system to fight the infection. To this point, all testing has been done with using transformed stem cells. “We have stem cells that we transform into white blood cells, then we trick them into thinking there’s an infection. We add those infection-response blood cells to human blood in the concentrations we want and the timeframe we want,” said Prof. Pappas. The blood is then tested to see if the chip registers it as septic. “That allows us to refine the technique to make sure it’ll work, because human samples are far more variable,” he said, “Before moving to humans, we had to show it’ll work in the first place.”
“Ultimately, this type of work – for it to be successful – has to be commercialized,” he said. “It has to be out there in the hands of physicians.” The next step is to test the chip with patient blood. In collaboration with Dr. Griswold, Dr. Pappas will now begin enrolling patients.
Related Links:
Texas Tech University
“Normally when you detect sepsis, you do it through bacterial culture; that takes two days on the short end to 15 days on the long end. Most people die of sepsis at two days. The detection currently is on the exact same time scale as mortality, so we’re trying to speed that up,” said Dimitri Pappas, associate professor of chemistry at Texas Tech University (Lubbock, TX, USA), “Instead of the bacteria, we’re looking at the body’s immune response to those bacteria, because that’s what you really care about: the bacteria cause the infection, but it’s the body’s response that causes sepsis.” It begins with a systemic inflammatory response then progresses into sepsis and eventually septic shock, in which blood pressure plummets and organs fail.
“In the elderly, in people who are immune-compromised – people who have had surgeries, for example, or burns or they’re already fighting off infection – and in children as well, you see a runaway immune response where the body’s act of saving itself can actually be lethal,” said Prof. Pappas. When not fatal, sepsis can result in amputation of a limb or prolonged hospitalization.
Sepsis is suspected by a patient’s abnormal body temperature and rapid heart and breathing rates. “Those are all incredibly crude measurements,” said Prof. Pappas, “It leads to a lot of false positives.” Because doctors know the bacterial culture likely will take longer than a septic patient’s life span, they often order treatment immediately. “The way they treat sepsis right now is through a massive antibiotic administration,” said Prof. Pappas “That’s good, actually, but if you do it prophylactically and when it’s not needed, you’re basically helping create drug-resistant bacteria. So there’s a need to detect sepsis and to treat it but not to over treat it.”
To successfully treat septic patients, doctors need two critical pieces of information: the microorganism causing the infection and whether it can be eradicated by antibiotics. “Waiting for that information over several days is one of the main problems and reasons for the devastating outcomes,” said Dr. John Griswold, professor and chair emeritus, Department of Surgery, TTU’s Health Sciences Center, “Dr. Pappas has developed a test that should give us at least the indication of bacterial invasion within a matter of hours as opposed to days. The sooner we have an indication of microorganism invasion, the sooner we are on the path to successful treatment of these very sick patients.” Prof. Griswold added that sepsis is considered one of the most costly diseases in healthcare.
Prof. Pappas and graduate student Ye Zhang recently filed a provisional patent for a microfluidics chip that can speed up detection. “We can take a blood sample, introduce it into this chip and capture one cell type or move fluids around and add chemicals to dye the cells certain colors and do diagnostic measurements,” said Prof. Pappas.
Using their chip, a sepsis diagnosis can be confirmed in just four hours. “That rapid detection will let doctors intervene sooner and intervene when necessary, but it also allows them not just to detect it but to follow up treatment,” said Prof. Pappas, “you can follow and retest them over time to make sure the body’s response is returning to normal.”
Another advantage is that the chip requires less than a drop of blood per test. “It’s so minimal we could do this multiple times throughout the course of the treatment of the patient. If they’re not septic at hour zero, but they still look septic by other methods, we could test them in six hours and see if they’ve progressed or not,” said Prof. Pappas.
The chips are designed to detect certain white blood cells activated by the immune system to fight the infection. To this point, all testing has been done with using transformed stem cells. “We have stem cells that we transform into white blood cells, then we trick them into thinking there’s an infection. We add those infection-response blood cells to human blood in the concentrations we want and the timeframe we want,” said Prof. Pappas. The blood is then tested to see if the chip registers it as septic. “That allows us to refine the technique to make sure it’ll work, because human samples are far more variable,” he said, “Before moving to humans, we had to show it’ll work in the first place.”
“Ultimately, this type of work – for it to be successful – has to be commercialized,” he said. “It has to be out there in the hands of physicians.” The next step is to test the chip with patient blood. In collaboration with Dr. Griswold, Dr. Pappas will now begin enrolling patients.
Related Links:
Texas Tech University
Latest Technology News
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more




.jpg)


